MCID: ACT177
MIFTS: 36

Acute Basophilic Leukemia

Categories: Blood diseases, Rare diseases, Cancer diseases

Aliases & Classifications for Acute Basophilic Leukemia

MalaCards integrated aliases for Acute Basophilic Leukemia:

Name: Acute Basophilic Leukemia 59 73

Classifications:



External Ids:

Orphanet 59 ORPHA86849
MESH via Orphanet 45 D015471
UMLS via Orphanet 74 C0023437
ICD10 via Orphanet 34 C94.7
UMLS 73 C0023437

Summaries for Acute Basophilic Leukemia

MalaCards based summary : Acute Basophilic Leukemia is related to leukemia, chronic myeloid and leukemia. An important gene associated with Acute Basophilic Leukemia is GATA1 (GATA Binding Protein 1), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and NF-kappaB Signaling. The drugs Lenograstim and Thiotepa have been mentioned in the context of this disorder. Affiliated tissues include myeloid, bone and bone marrow, and related phenotypes are Increased shRNA abundance (Z-score > 2) and Increased shRNA abundance (Z-score > 2)

Wikipedia : 76 Acute basophilic leukemia is a rare form of acute myeloid leukemia where blasts are accompanied by... more...

Related Diseases for Acute Basophilic Leukemia

Graphical network of the top 20 diseases related to Acute Basophilic Leukemia:



Diseases related to Acute Basophilic Leukemia

Symptoms & Phenotypes for Acute Basophilic Leukemia

GenomeRNAi Phenotypes related to Acute Basophilic Leukemia according to GeneCards Suite gene sharing:

26 (show all 38)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 10.49 CSF2RA MPO MYB
2 Increased shRNA abundance (Z-score > 2) GR00366-A-101 10.49 ETV6
3 Increased shRNA abundance (Z-score > 2) GR00366-A-102 10.49 CSF2RA
4 Increased shRNA abundance (Z-score > 2) GR00366-A-105 10.49 CSF2RA
5 Increased shRNA abundance (Z-score > 2) GR00366-A-11 10.49 CSF2RA
6 Increased shRNA abundance (Z-score > 2) GR00366-A-115 10.49 CSF2RA
7 Increased shRNA abundance (Z-score > 2) GR00366-A-120 10.49 MYB
8 Increased shRNA abundance (Z-score > 2) GR00366-A-121 10.49 MYB
9 Increased shRNA abundance (Z-score > 2) GR00366-A-122 10.49 MYB
10 Increased shRNA abundance (Z-score > 2) GR00366-A-126 10.49 MPO
11 Increased shRNA abundance (Z-score > 2) GR00366-A-137 10.49 CSF2RA ETV6
12 Increased shRNA abundance (Z-score > 2) GR00366-A-146 10.49 CSF2RA
13 Increased shRNA abundance (Z-score > 2) GR00366-A-147 10.49 MYB
14 Increased shRNA abundance (Z-score > 2) GR00366-A-151 10.49 ETV6 CSF2RA
15 Increased shRNA abundance (Z-score > 2) GR00366-A-157 10.49 MPO
16 Increased shRNA abundance (Z-score > 2) GR00366-A-159 10.49 ETV6
17 Increased shRNA abundance (Z-score > 2) GR00366-A-161 10.49 MYB
18 Increased shRNA abundance (Z-score > 2) GR00366-A-164 10.49 MYB
19 Increased shRNA abundance (Z-score > 2) GR00366-A-169 10.49 MYB
20 Increased shRNA abundance (Z-score > 2) GR00366-A-176 10.49 ETV6 MPO
21 Increased shRNA abundance (Z-score > 2) GR00366-A-177 10.49 MYB
22 Increased shRNA abundance (Z-score > 2) GR00366-A-186 10.49 MPO
23 Increased shRNA abundance (Z-score > 2) GR00366-A-198 10.49 ETV6
24 Increased shRNA abundance (Z-score > 2) GR00366-A-202 10.49 ETV6
25 Increased shRNA abundance (Z-score > 2) GR00366-A-215 10.49 CSF2RA
26 Increased shRNA abundance (Z-score > 2) GR00366-A-23 10.49 CSF2RA
27 Increased shRNA abundance (Z-score > 2) GR00366-A-29 10.49 MPO
28 Increased shRNA abundance (Z-score > 2) GR00366-A-32 10.49 CSF2RA
29 Increased shRNA abundance (Z-score > 2) GR00366-A-36 10.49 MPO
30 Increased shRNA abundance (Z-score > 2) GR00366-A-50 10.49 CSF2RA
31 Increased shRNA abundance (Z-score > 2) GR00366-A-52 10.49 ETV6
32 Increased shRNA abundance (Z-score > 2) GR00366-A-57 10.49 MPO
33 Increased shRNA abundance (Z-score > 2) GR00366-A-7 10.49 MPO
34 Increased shRNA abundance (Z-score > 2) GR00366-A-70 10.49 MPO
35 Increased shRNA abundance (Z-score > 2) GR00366-A-73 10.49 MYB CSF2RA ETV6
36 Increased shRNA abundance (Z-score > 2) GR00366-A-83 10.49 MYB
37 Increased shRNA abundance (Z-score > 2) GR00366-A-96 10.49 CSF2RA
38 Reduced mammosphere formation GR00396-S 9.02 CSF2RA ETV6 GATA1 IL18R1 IL3RA

MGI Mouse Phenotypes related to Acute Basophilic Leukemia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 9.43 ETV6 GATA1 IL18R1 IL3RA MPO MYB
2 immune system MP:0005387 9.1 ETV6 GATA1 IL18R1 IL3RA MPO MYB

Drugs & Therapeutics for Acute Basophilic Leukemia

Drugs for Acute Basophilic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 108)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Lenograstim Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 135968-09-1
2
Thiotepa Approved, Investigational Phase 4,Phase 1 52-24-4 5453
3
Cyclophosphamide Approved, Investigational Phase 4,Phase 2,Phase 1 50-18-0, 6055-19-2 2907
4 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
5 Alkylating Agents Phase 4,Phase 3,Phase 2,Phase 1
6 Antilymphocyte Serum Phase 4,Phase 2
7 Antirheumatic Agents Phase 4,Phase 2,Phase 1
8 Antineoplastic Agents, Alkylating Phase 4,Phase 3,Phase 2,Phase 1
9
Cytarabine Approved, Investigational Phase 3,Phase 2,Phase 1 147-94-4 6253
10
alemtuzumab Approved, Investigational Phase 2, Phase 3 216503-57-0
11
Fludarabine Approved Phase 2, Phase 3,Phase 3,Phase 1 21679-14-1, 75607-67-9 30751
12
Etoposide Approved Phase 3,Phase 2,Phase 1 33419-42-0 36462
13
Clofarabine Approved, Investigational Phase 2, Phase 3,Phase 1 123318-82-1 119182
14
Busulfan Approved, Investigational Phase 3,Phase 2 55-98-1 2478
15
Melphalan Approved Phase 2, Phase 3 148-82-3 4053 460612
16
Mitoxantrone Approved, Investigational Phase 3,Phase 2,Phase 1 65271-80-9 4212
17
Daunorubicin Approved Phase 3,Phase 2,Phase 1 20830-81-3 30323
18
Thioguanine Approved Phase 3 154-42-7 2723601
19
Azacitidine Approved, Investigational Phase 2, Phase 3,Phase 1 320-67-2 9444
20
Aldesleukin Approved Phase 3,Phase 2 85898-30-2, 110942-02-4
21
Arsenic trioxide Approved, Investigational Phase 2, Phase 3,Phase 1 1327-53-3 518740
22
Dexamethasone Approved, Investigational, Vet_approved Phase 3 50-02-2 5743
23
tipifarnib Investigational Phase 2, Phase 3,Phase 1 192185-72-1 159324
24 Staurosporine Experimental Phase 3 62996-74-1
25 Gemtuzumab Phase 2, Phase 3,Phase 3
26 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1
27 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1
28 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1
29 Anti-Infective Agents Phase 3,Phase 2,Phase 1
30 Antimetabolites Phase 3,Phase 2,Phase 1
31 Antiviral Agents Phase 3,Phase 2,Phase 1
32 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1
33 Interleukin-2 Phase 3
34 Analgesics Phase 3,Phase 2,Phase 1
35
asparaginase Phase 3
36 Analgesics, Non-Narcotic Phase 3
37 N-Methylaspartate Phase 3
38 Peripheral Nervous System Agents Phase 3,Phase 2,Phase 1
39 Etoposide phosphate Phase 3,Phase 2,Phase 1
40 Anti-HIV Agents Phase 3,Phase 2
41 Protein Kinase Inhibitors Phase 3,Phase 2,Phase 1
42 Anti-Retroviral Agents Phase 3,Phase 2
43 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
44 Dexamethasone acetate Phase 3 1177-87-3
45 glucocorticoids Phase 3
46
protease inhibitors Phase 3
47 4'-N-benzoylstaurosporine Phase 3
48 Gastrointestinal Agents Phase 3
49 HIV Protease Inhibitors Phase 3
50 Hormone Antagonists Phase 3

Interventional clinical trials:

(show top 50) (show all 60)
# Name Status NCT ID Phase Drugs
1 Bone Marrow Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003398 Phase 4 cyclophosphamide;thiotepa
2 Gemtuzumab Ozogamicin in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Unknown status NCT00091234 Phase 2, Phase 3 gemtuzumab ozogamicin
3 Combination Chemotherapy With or Without PSC 833, Peripheral Stem Cell Transplantation, and/or Interleukin-2 in Treating Patients With Acute Myeloid Leukemia Completed NCT00006363 Phase 3 cytarabine;daunorubicin hydrochloride;etoposide;valspodar;busulfan
4 Combination Chemotherapy in Treating Young Patients With Down Syndrome and Acute Myeloid Leukemia or Myelodysplastic Syndromes Completed NCT00369317 Phase 3 asparaginase;daunorubicin hydrochloride;cytarabine;thioguanine;etoposide
5 Combination Chemotherapy With or Without Gemtuzumab in Treating Young Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT00372593 Phase 3 asparaginase;cytarabine;daunorubicin hydrochloride;etoposide;gemtuzumab ozogamicin;mitoxantrone hydrochloride
6 S0106 Cytarabine and Daunorubicin w/ or w/o Gemtuzumab Followed By HD Cytarabine and Either Gemtuzumab or Nothing in de Novo AML Completed NCT00085709 Phase 3 gemtuzumab ozogamicin;Cytosine arabinoside;Daunomycin
7 Combination Chemotherapy With or Without Gemtuzumab Ozogamicin or Tipifarnib in Treating Patients With Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndromes Completed NCT00454480 Phase 2, Phase 3 arsenic trioxide;azacitidine;busulfan;clofarabine;cytarabine;daunorubicin hydrochloride;fludarabine phosphate;gemtuzumab ozogamicin;melphalan;tipifarnib
8 Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia Completed NCT00112554 Phase 3 cytarabine;laromustine
9 Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Active, not recruiting NCT00651261 Phase 3 cytarabine;daunorubicin;midostaurin;dexamethasone acetate
10 Combination Chemotherapy in Treating Patients With Relapsed Acute Myelogenous Leukemia Unknown status NCT00003758 Phase 2 cytarabine;idarubicin
11 VNP40101M Followed by Cytarabine in Treating Older Patients With Acute Myeloid Leukemia Unknown status NCT00354276 Phase 2 cytarabine;laromustine
12 Alvocidib, Cytarabine, and Mitoxantrone in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Completed NCT00407966 Phase 2 alvocidib;cytarabine;mitoxantrone hydrochloride
13 Lenalidomide in Treating Older Patients With Acute Myeloid Leukemia Completed NCT00352365 Phase 2 lenalidomide
14 Idarubicin, Cytarabine, and Tipifarnib in Treating Patients With Newly Diagnosed Myelodysplastic Syndromes or Acute Myeloid Leukemia Completed NCT00096122 Phase 1, Phase 2 cytarabine;idarubicin;tipifarnib
15 Tipifarnib in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia Completed NCT00027872 Phase 2 tipifarnib
16 Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia Completed NCT00666588 Phase 2 idarubicin;cytarabine;bortezomib;etoposide
17 Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer Completed NCT00003396 Phase 2 cyclophosphamide;melphalan
18 Clofarabine and Temsirolimus in Treating Older Patients With Relapsed or Refractory Acute Myeloid Leukemia Completed NCT00775593 Phase 2 clofarabine;temsirolimus
19 Early Discharge and Outpatients Care in Patients With Myelodysplastic Syndrome or Acute Myeloid Leukemia Previously Treated With Intensive Chemotherapy Completed NCT01235572 Phase 2
20 A Phase II Open-Label Study of High-Dose Cytarabine and Clofarabine in Adult Patients With Refractory or Relapsed Acute Myelogenous Leukemia or Refractory or Relapsed Acute Lymphoblastic Leukemia Completed NCT01656031 Phase 2 clofarabine;cytarabine
21 Gemtuzumab Ozogamicin and Cyclosporine in Treating Older Patients With Relapsed Acute Myeloid Leukemia Completed NCT00089050 Phase 2 cyclosporine;gemtuzumab ozogamicin
22 S0112 Cytarabine and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia Completed NCT00023777 Phase 2 cytarabine;daunorubicin hydrochloride
23 Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy Recruiting NCT02071901 Phase 2 eltrombopag olamine
24 Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia Active, not recruiting NCT01627041 Phase 2 Cytarabine;Daunorubicin Hydrochloride;Decitabine
25 Busulfan, Etoposide, and Total-Body Irradiation Followed by Autologous Stem Cell Transplant and Aldesleukin in Treating Patients With Acute Myeloid Leukemia in First Remission Active, not recruiting NCT00534469 Phase 2 busulfan;cytarabine;etoposide;idarubicin
26 Imatinib Mesylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Who Have Received Chemotherapy Active, not recruiting NCT00509093 Phase 2 imatinib mesylate
27 Idarubicin and Cytarabine With or Without Bevacizumab in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Terminated NCT00096148 Phase 2 idarubicin;cytarabine
28 Cilengitide in Treating Patients With Acute Myeloid Leukemia Terminated NCT00089388 Phase 2 cilengitide
29 Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase Completed NCT00383474 Phase 1 Bortezomib;Tipifarnib
30 Sorafenib in Treating Patients With Refractory or Relapsed Acute Leukemia, Myelodysplastic Syndromes, or Blastic Phase Chronic Myelogenous Leukemia Completed NCT00217646 Phase 1 Sorafenib Tosylate
31 Sorafenib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia Completed NCT00131989 Phase 1 sorafenib tosylate
32 XK469R in Treating Patients With Refractory Hematologic Cancer Completed NCT00095797 Phase 1 R(+)XK469
33 Vorinostat, Cytarabine, and Etoposide in Treating Patients With Relapsed and/or Refractory Acute Leukemia or Myelodysplastic Syndromes or Myeloproliferative Disorders Completed NCT00357305 Phase 1 vorinostat;cytarabine;etoposide
34 Tanespimycin and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myelogenous Leukemia, Chronic Myelomonocytic Leukemia, or Myelodysplastic Syndromes Completed NCT00098423 Phase 1 tanespimycin;cytarabine
35 Clofarabine and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Leukemia, Chronic Myelogenous Leukemia, or Myeloproliferative Disorders Completed NCT00293410 Phase 1 clofarabine;cyclophosphamide
36 Chemotherapy, Radiation Therapy, and Peripheral Stem Cell Transplantation in Treating Patients With Hematologic Cancer Completed NCT00005092 Phase 1 Cyclophosphamide;Psoralen;Thiotepa
37 Tipifarnib, Cytarabine, and Daunorubicin in Treating Older Patients With Acute Myeloid Leukemia Completed NCT00101153 Phase 1 cytarabine;daunorubicin hydrochloride;tipifarnib
38 Arsenic Trioxide, Cytarabine, and Idarubicin in Treating Patients With Acute Myeloid Leukemia Completed NCT00093483 Phase 1 arsenic trioxide;cytarabine;idarubicin
39 Cladribine, Cytarabine, and Imatinib Mesylate in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Blastic Phase Chronic Myelogenous Leukemia Completed NCT00258271 Phase 1 cladribine;cytarabine;imatinib mesylate
40 Cytarabine and Clofarabine in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia Completed NCT00295841 Phase 1 clofarabine;cytarabine
41 Decitabine and FR901228 in Treating Patients With Relapsed or Refractory Leukemia, Myelodysplastic Syndromes, or Myeloproliferative Disorders Completed NCT00114257 Phase 1 decitabine;romidepsin
42 Arsenic Trioxide in Treating Patients With Advanced Hematologic Cancer Completed NCT00003395 Phase 1 arsenic trioxide
43 3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic Syndrome Completed NCT00077558 Phase 1 fludarabine phosphate;triapine
44 Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy Completed NCT00030108 Phase 1 ixabepilone
45 Everolimus MICE-regimen in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Active, not recruiting NCT01154439 Phase 1 cytarabine;etoposide;everolimus;idarubicin;mitoxantrone hydrochloride
46 Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia Terminated NCT01550185 Phase 1 eltrombopag olamine
47 Entinostat and Sorafenib Tosylate in Treating Patients With Advanced or Metastatic Solid Tumors or Refractory or Relapsed Acute Myeloid Leukemia Terminated NCT01159301 Phase 1 entinostat;sorafenib tosylate
48 Azacitidine, Mitoxantrone Hydrochloride, and Etoposide in Treating Older Patients With Poor-Prognosis Acute Myeloid Leukemia Terminated NCT01260714 Phase 1 Azacitidine;Etoposide;Mitoxantrone Hydrochloride
49 17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer Terminated NCT00103272 Phase 1 tanespimycin;bortezomib
50 Flavopiridol in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, or Chronic Myelogenous Leukemia Terminated NCT00101231 Phase 1 alvocidib

Search NIH Clinical Center for Acute Basophilic Leukemia

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Genetic Tests for Acute Basophilic Leukemia

Anatomical Context for Acute Basophilic Leukemia

MalaCards organs/tissues related to Acute Basophilic Leukemia:

41
Myeloid, Bone, Bone Marrow, Liver, Testes

Publications for Acute Basophilic Leukemia

Articles related to Acute Basophilic Leukemia:

(show all 30)
# Title Authors Year
1
Acute basophilic leukemia associated with the t(16;21)(p11;q22)/<i>FUS</i>-<i>ERG</i>fusion gene. ( 29225830 )
2017
2
Acute basophilic leukemia with add(3)(q12) accompanied by histamine excess symptoms. ( 28424883 )
2017
3
Acute basophilic leukemia presenting with maculopapular rashes and a gastric ulcer: A case report. ( 25364419 )
2014
4
Acute basophilic leukemia. ( 24949509 )
2014
5
A case of Langerhans cell histiocytosis following acute basophilic leukemia. ( 22895553 )
2013
6
Arsenic trioxide in treatment of de novo acute basophilic leukemia. ( 23422134 )
2013
7
Acute basophilic leukemia in an infant with proptosis. ( 21393925 )
2011
8
Trisomy 19 and t(9;22) in a patient with acute basophilic leukemia. ( 22937382 )
2011
9
Acute basophilic leukemia associated with loss of gene ETV6 and protean complications. ( 21576634 )
2011
10
Identification of a transforming MYB-GATA1 fusion gene in acute basophilic leukemia: a new entity in male infants. ( 21474671 )
2011
11
A case of acute basophilic leukemia arising from chronic myelogenous leukemia with development of t(7;8)(q32;q13). ( 18328951 )
2008
12
Monosomy 7 as the sole abnormality of an acute basophilic leukemia. ( 17213028 )
2007
13
Imatinib resistant chronic myelogenous leukemia, BCR-ABL positive by chromosome and FISH analyses but negative by PCR, in a child progressing to acute basophilic leukemia: cytogenetic follow-up. ( 16965955 )
2006
14
Acute basophilic leukemia with t(8;21). ( 15160925 )
2004
15
Acute basophilic leukemia: case report. ( 15164378 )
2004
16
Acute basophilic leukemia lacking basophil-specific antigens: the importance of cytokine receptor expression in differential diagnosis. ( 11999362 )
2002
17
Acute basophilic leukemia. ( 11722593 )
2001
18
Acute basophilic leukemia presenting with abnormal liver function tests and the absence of blast cells in the peripheral blood. ( 10740808 )
2000
19
Diagnosis of acute basophilic leukemia. ( 10037024 )
1999
20
Acute basophilic leukemia in a child. Anaphylactoid reaction and coagulopathy secondary to vincristine-mediated degranulation. ( 7804964 )
1995
21
An abnormal clone with monosomy 7 and trisomy 21 in the bone marrow of a child with congenital agranulocytosis (Kostmann disease) treated with granulocyte colony-stimulating factor. Evolution towards myelodysplastic syndrome and acute basophilic leukemia. ( 8536230 )
1995
22
[Acute basophilic leukemia: a case report]. ( 7689662 )
1993
23
Acute basophilic leukemia and acute eosinophilic leukemia after therapy for non-Hodgkin's lymphoma. ( 8257517 )
1993
24
Acute basophilic leukemia. ( 1489389 )
1992
25
Acute basophilic leukemia. A case report. ( 1718580 )
1991
26
Evolution of the French-American-British (FAB) proposals. Is there a place for acute basophilic leukemia? ( 1862770 )
1991
27
Acute basophilic leukemia. A clinical, morphologic, and cytogenetic study of eight cases. ( 1862771 )
1991
28
Acute basophilic leukemia. ( 6731465 )
1984
29
Follow-up of sixty two cases of acute basophilic leukemia. ( 667277 )
1978
30
Mast cell leukemia and acute basophilic leukemia. Cytochemical studies. ( 747630 )
1978

Variations for Acute Basophilic Leukemia

Expression for Acute Basophilic Leukemia

Search GEO for disease gene expression data for Acute Basophilic Leukemia.

Pathways for Acute Basophilic Leukemia

GO Terms for Acute Basophilic Leukemia

Biological processes related to Acute Basophilic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 regulation of hematopoietic stem cell differentiation GO:1902036 8.62 GATA1 MYB

Molecular functions related to Acute Basophilic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 RNA polymerase II proximal promoter sequence-specific DNA binding GO:0000978 9.33 ETV6 GATA1 MYB
2 cytokine receptor activity GO:0004896 8.96 CSF2RA IL3RA
3 transcriptional activator activity, RNA polymerase II proximal promoter sequence-specific DNA binding GO:0001077 8.8 ETV6 GATA1 MYB

Sources for Acute Basophilic Leukemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....